Please login to the form below

Not currently logged in
Email:
Password:

Abbott completes $6.2bn Solvay acquisition

Abbott has announced that it has completed its acquisition of Solvay Pharmaceuticals in a deal worth $6.2bn (€4.5bn)

Abbott has announced that it has completed its acquisition of Solvay Pharmaceuticals in a deal worth $6.2bn (€4.5bn). The takeover of the Belgian company provides Abbott with a large and complementary portfolio of pharmaceutical products, helping to expand the company' presence in key global emerging markets.

"The acquisition of Solvay Pharmaceuticals is a key part of Abbott's strategy to bolster our presence in key markets and deliver sustainable, industry-leading growth," said Miles D White, chairman and CEO of Abbott.

"In addition to taking both Abbott and Solvay products into new and expanding markets, the acquisition enhances our R&D investment, providing Abbott with the opportunity to drive future pharmaceutical growth."

The acquisition is expected to add around $2.9bn to Abbott's total reported sales for 2010. The majority of which will be outside the US and will add around $500m to the company's annual pharmaceutical R&D investment.

Included in the deal are milestone payments of up to €300m if certain sales points are met between 2011 and 2013.

The products gained from Solvay include treatments for men's and women's hormonal health; and exocrine pancreatic insufficiency (inability to properly digest food), which is associated with several underlying conditions including cystic fibrosis and chronic pancreatitis. These therapies will complement Abbott's presence and expertise in speciality markets such as cardiovascular disease, neuroscience and gastroenterology and help Abbott to further diversify its business, providing significant growth opportunities.

Olivier Bohuon, executive vice president, Pharmaceutical Products Group at Abbott said: "The addition of Solvay Pharmaceuticals is the catalyst for Abbott's growth and leadership in this [key emerging markets] area, and will ensure Abbott has the infrastructure, reach and product offerings to continue meeting the needs of patients around the world."

17th February 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics